{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T15:14:56Z","timestamp":1791213296292,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2014,7,18]],"date-time":"2014-07-18T00:00:00Z","timestamp":1405641600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s00280-014-2523-8","type":"journal-article","created":{"date-parts":[[2014,7,17]],"date-time":"2014-07-17T10:05:07Z","timestamp":1405591507000},"page":"637-646","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Phase I clinical trial of pegylated liposomal mitoxantrone plm60-s: pharmacokinetics, toxicity and preliminary efficacy"],"prefix":"10.1007","volume":"74","author":[{"given":"Jianliang","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuankai","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunlei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Gui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaohong","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxiang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,7,18]]},"reference":[{"issue":"6 Suppl 12","key":"2523_CR1","first-page":"37","volume":"27","author":"P McLaughlin","year":"2000","unstructured":"McLaughlin P, Hagemeister FB, Rodriguez MA, Sarris AH, Pate O, Younes A et al (2000) Safety of fludarabine, mitoxantrone, and dexamethasone combined with rituximab in the treatment of stage IV indolent lymphoma. Semin Oncol 27(6 Suppl 12):37\u201341","journal-title":"Semin Oncol"},{"issue":"3 Suppl 1","key":"2523_CR2","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/S0090-4295(02)01583-2","volume":"60","author":"T Gilligan","year":"2002","unstructured":"Gilligan T, Kantoff PW (2002) Chemotherapy for prostate cancer. Urology 60(3 Suppl 1):94\u2013100 discussion 100","journal-title":"Urology"},{"issue":"6","key":"2523_CR3","first-page":"1257","volume":"7","author":"H Lenk","year":"1987","unstructured":"Lenk H, Muller U, Tanneberger S (1987) Mitoxantrone: mechanism of action, antitumor activity, pharmacokinetics, efficacy in the treatment of solid tumors and lymphomas, and toxicity. Anticancer Res 7(6):1257\u20131264","journal-title":"Anticancer Res"},{"issue":"12 Suppl 6","key":"2523_CR4","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1212\/WNL.63.12_suppl_6.S15","volume":"63","author":"EJ Fox","year":"2004","unstructured":"Fox EJ (2004) Mechanism of action of mitoxantrone. Neurology 63(12 Suppl 6):S15\u2013S18","journal-title":"Neurology"},{"issue":"2","key":"2523_CR5","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/14740338.4.2.219","volume":"4","author":"K Seiter","year":"2005","unstructured":"Seiter K (2005) Toxicity of the topoisomerase II inhibitors. Expert Opin Drug Saf 4(2):219\u2013234","journal-title":"Expert Opin Drug Saf"},{"issue":"5","key":"2523_CR6","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-199856050-00001","volume":"56","author":"TM Allen","year":"1998","unstructured":"Allen TM (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56(5):747\u2013756","journal-title":"Drugs"},{"issue":"Suppl 4","key":"2523_CR7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.2165\/00003495-199700544-00004","volume":"54","author":"TM Allen","year":"1997","unstructured":"Allen TM (1997) Liposomes. Opportunities in drug delivery. Drugs 54(Suppl 4):8\u201314","journal-title":"Drugs"},{"issue":"5","key":"2523_CR8","first-page":"3313","volume":"21","author":"PC Gokhale","year":"2001","unstructured":"Gokhale PC, Pei J, Zhang C, Ahmad I, Rahman A, Kasid U (2001) Improved safety, pharmacokinetics and therapeutic efficacy profiles of a novel liposomal formulation of mitoxantrone. Anticancer Res 21(5):3313\u20133321","journal-title":"Anticancer Res"},{"issue":"4\u20135","key":"2523_CR9","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.ejps.2008.05.006","volume":"34","author":"C Li","year":"2008","unstructured":"Li C, Cui J, Li Y, Wang C, Li Y, Zhang L, Zhang L, Guo W, Wang J, Zhang H, Hao Y, Wang Y (2008) Copper ion-mediated liposomal encapsulation of mitoxantrone: the role of anions in drug loading, retention and release. Eur J Pharm Sci 34(4\u20135):333\u2013344","journal-title":"Eur J Pharm Sci"},{"issue":"2","key":"2523_CR10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/j.ejpb.2008.05.019","volume":"70","author":"C Li","year":"2008","unstructured":"Li C, Cui J, Wang C, Li Y, Zhang H, Wang J, Li Y, Zhang L, Zhang L, Guo W, Wang Y (2008) Encapsulation of mitoxantrone into pegylated SUVs enhances its antineoplastic efficacy. Eur J Pharm Biopharm 70(2):657\u2013665","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"2523_CR11","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1016\/S0022-3565(24)36596-6","volume":"281","author":"HJ Lim","year":"1997","unstructured":"Lim HJ, Masin D, Madden TD, Bally MB (1997) Influence of drug release characteristics on the therapeutic activity of liposomal mitoxantrone. J Pharmacol Exp Ther 281(1):566\u2013573","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"2523_CR12","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/0959-8049(95)00010-0","volume":"31A","author":"BC Pestalozzi","year":"1995","unstructured":"Pestalozzi BC, Vass A, Adam H, Horber DH, Schwendener RA, Sauter C (1995) Phase II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Eur J Cancer 31A(6):1024","journal-title":"Eur J Cancer"},{"issue":"1","key":"2523_CR13","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/S0022-3565(24)35297-8","volume":"292","author":"HJ Lim","year":"2000","unstructured":"Lim HJ, Masin D, McIntosh NL, Madden TD, Bally MB (2000) Role of drug release and liposome-mediated drug delivery in governing the therapeutic activity of liposomal mitoxantrone used to treat human A431 and LS180 solid tumors. J Pharmacol Exp Ther 292(1):337\u2013345","journal-title":"J Pharmacol Exp Ther"},{"issue":"1\u20132","key":"2523_CR14","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.ijpharm.2013.10.023","volume":"460","author":"C Li","year":"2014","unstructured":"Li C, Zhao X, Deng C, Wang C, Wei N, Cui J (2014) Pegylated liposomal mitoxantrone is more therapeutically active than mitoxantrone in L1210 ascitic tumor and exhibits dose-dependent activity saturation effect. Int J Pharm 460(1\u20132):165\u2013172","journal-title":"Int J Pharm"},{"issue":"12","key":"2523_CR15","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1093\/annonc\/mdp287","volume":"20","author":"M Cirillo","year":"2009","unstructured":"Cirillo M, Venturini M, Ciccarelli L, Coati F, Bortolami O, Verlato G (2009) Clinician versus nurse symptom reporting using the National Cancer Institute-Common Terminology Criteria for Adverse Events during chemotherapy: results of a comparison based on patient\u2019s self-reported questionnaire. Ann Oncol 20(12):1929\u20131935","journal-title":"Ann Oncol"},{"issue":"1","key":"2523_CR16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mpo.1154","volume":"37","author":"Y Tsuchida","year":"2001","unstructured":"Tsuchida Y, Therasse P (2001) Response evaluation criteria in solid tumors (RECIST): new guidelines. Med Pediatr Oncol 37(1):1\u20133","journal-title":"Med Pediatr Oncol"},{"issue":"5","key":"2523_CR17","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586","journal-title":"J Clin Oncol"},{"issue":"6","key":"2523_CR18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/oxfordjournals.annonc.a058232","volume":"3","author":"B Pestalozzi","year":"1992","unstructured":"Pestalozzi B, Schwendener R, Sauter C (1992) Phase I\/II study of liposome-complexed mitoxantrone in patients with advanced breast cancer. Ann Oncol 3(6):445\u2013449","journal-title":"Ann Oncol"},{"issue":"6","key":"2523_CR19","first-page":"567","volume":"18","author":"J Szebeni","year":"2001","unstructured":"Szebeni J (2001) Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents. Crit Rev Ther Drug Carrier Syst 18(6):567\u2013606","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"key":"2523_CR20","doi-asserted-by":"crossref","unstructured":"Szebeni J, Muggia F, Gabizon A, Barenholz Y (2011) Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention. Adv Drug Deliv Rev 63(12):1020\u20131030","DOI":"10.1016\/j.addr.2011.06.017"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2523-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-014-2523-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-014-2523-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T17:10:15Z","timestamp":1746292215000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-014-2523-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,7,18]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["2523"],"URL":"https:\/\/doi.org\/10.1007\/s00280-014-2523-8","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,7,18]]}}}